Phathom Pharmaceuticals
About
Phathom Pharmaceuticals is a biopharmaceutical company.
- 51 - 100
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $40M
- Industries
- Biotechnology,Pharmaceutical
- Founded date
- Jan 1, 2018
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the clinical drug candidate vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.Phathom has assembled a leading team of seasoned gastrointestinal and pharmaceutical industry experts with proven experience developing and commercializing highly innovative therapies.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 1, 2022 | Post-IPO Debt | $40M | 2 | — | — | Detail |
| Sep 20, 2021 | Post-IPO Debt | $200M | 1 |
Hercules Capital
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Hercules Capital
|
— | Post-IPO Debt |
|
|
— | Post-IPO Debt |
